Company intelligence / Profile preview

White Heart

Winchester, England, United Kingdomwhiteheart.org ↗

Ownership: Private
Development stage: Other

Overview

Heart Biotech has demonstrated full regrowth of nerve tissue, blood vessels, and adipose tissue using its Yacoub Valve® platform in preclinical studies. The technology enables a patient’s own cells to colonize a synthetic scaffold that dissolves over time, resulting in a living heart valve that grows and adapts with the patient. This approach aims to eliminate repeat surgeries for children and reduce lifelong medication needs.

Therapeutic areas: Cardiovascular
Modalities: Scaffold-based therapyIn-situ tissue engineeringBiomaterial scaffold (cell-free)
Industry: Implantable Medical Devices

Beyond the preview

Go deeper on White Heart.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on White Heart.

Explore the full profile